chrisvoncsefalvay/vaers-outcomes huggingface dataset:
My left arm was sore on day of and day after vaccine. I took Aleve (2 tabs q 12 hrs) on 12/31/2020. I didn?t notice or look for anything after that. On approximately 01/07/2021 I noticed area around injection was raised/hard/red and warm.  I took more Aleve on that day and the day after. Area remained red/warm/hard and red area had gotten larger until 01/10/2021 when I went to an urgent care/walk in clinic. The PA who tended to me took blood. Reports showed increase in eosinophils. She prescribed Augmentin 875 (1 tab BID) and Hydroxyzine HCL 50mg (1 tab TID). I?ve been taking the hydroxyzine at bedtime only on 01/10, 11, and 12 bc of drowsiness side effect. Started the TID dosing 01/13. On 01/12 the warmth and hardness/swelling around the injection site had disappeared. On 01/13 redness has diminished above the elbow ,however, redness has traveled to elbow and under. I have 7 days left on antibiotic and 3 days on antihistamine.
Large red welt, baseball in size. Felt flu like for few days. 2-3 weeks post dose, arthritis symptoms started. Arthritis of left shoulder continues with progressing weakness. Pt first reports this to pharmacy on 4/22/19, has not yet reported to MD. Reported to MD on 4/23/19.
related to anxiety; Only slept about an hour; Light headed; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Light headed), INSOMNIA (Only slept about an hour) and ANXIETY (related to anxiety) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041J21A) for COVID-19 vaccination.     The patient's past medical history included Anxiety. Concurrent medical conditions included Hypertension.   On 03-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On 03-Sep-2021, the patient experienced DIZZINESS (Light headed). On 06-Sep-2021, the patient experienced INSOMNIA (Only slept about an hour). On an unknown date, the patient experienced ANXIETY (related to anxiety). At the time of the report, DIZZINESS (Light headed), INSOMNIA (Only slept about an hour) and ANXIETY (related to anxiety) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 03-Sep-2021, Heart rate increased: 105 bpm (High) heart rate went up to 105 bpm. On 07-Sep-2021, Heart rate increased: 99bpm (High) heart rate goes up to 99bpm upon rising.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   No concurrent medication was reported by patient. patient reported treatment as Sits Back down, Deep breaths, Relaxes.  Patient reported that her rate would go back down when she would sit back down, take some deep breaths and relax. patient reported that this happened a little bit on the second day, but the third day after vaccination she was great.
Patient had PENTACEL & VARIVAX on 7/6/12 patient seen in ER. 7/8/12 - patient had hives on abd., back and face.
I had vaccination on 10/23/2022. I started to experience 11/29/2022 symptoms to include a cough and congestion. I took a COVID-19 test on 12/01/2022 and it was positive. I called my doctor office within an hour and they prescribed PAXLOVID. I started medication on 12/01/2022. My O2 stats have been within the 90%. I currently feel ok except a chest cough on 12/06/2022.
Narrative: Per PCP note on 03/03/2021, "I spoke w/the pt's wife (pt w/ dementia) who received his covid vaccine in early february. Pt was fine but at night the pt started to take deeper breaths. Wife noted he was somewhat agitated and felt he was having some sob. There was no cough, no URI sx's, no wheezing, no rash or hives, no obvious tongue or face swelling. Pt improved after a neb tx. Pt was not sick before his vaccine and his sx's resolved after his nebulizer tx. In am he was given a second tx and has been fine since. Pt's wife is concerned and wants to now if he should get his second vaccine. I recommended for her to not give him his second vaccine. If the Johnson and johnson vaccine becomes available they can aske for that one. Wife agreed to hold the second vaccine."
Patient was fully vaccinated with Janssen on 11/3/2021, but received Moderna booster dose today 12/8/2021. Patient aware of early booster.
Patient received IPV, Infarix, MMRV-Proquad, Hepatitis B, and Influenza vaccines at 2:30 PM and had a rash at 6:00 PM.
I received my first COVID vaccination on 12/23/2020. Within 24 hours I had a very painful arm at the injection site & flu like s/s such as HA & myalgias. This continued & on 12/29/2020 I began to have an irritated bronchial & even stayed home from work this day. Each day the s/s progressed & by Monday 1/4/2021 I was beginning to have wheezing and chest congestion, productive cough, & SOB, diarrhea, & abdominal pain. The last symptom I have had was the horrible mouth lesions.  I worked on Monday 1/4/2021 sick but then was off on 1/5, 1/6, 1/7, 1/8, & Monday 1/11/2019. Throughout my time of not feeling well I never ran a fever. On Friday 1/8/2021 I had a negative COVID test through the respiratory clinic. I did a round of antibiotics & even a round of steroids. I was last seen on Monday 1/11/2021 by the AMG PCP & was given the magic mouthwash.   The mouth lesions have since gone away but I continue to have intermittent SOB, wheezing, and a productive cough. At this time I will wait until I am completely better to take the second vaccine. I just want to remind you that I did register through the CDC VSAFE program & continue to answer their questions through text & made them aware of the problems I have had since taking the vaccine. As discussed please file this documentation in my employee health file. My office coordinators have been very helpful & understanding throughout this time. appreciate all you do. Thank you.
A 9 month old female received the 1st dose of Prevnar and Recombivax-HB (MSD) on 6/15/00 and within 12 to 15 hours, post vax, developed fever of 103F, vomiting and small macules on her anterior and posterior trunk, neck and back of ears. The reporter indicated that the pt was treated with Tylenol or Motrin for the elevated temperature.
PALPITATIONS; HEADACHE; FEVER; This spontaneous report received from a patient concerned a female of unspecified age. The patient's height, and weight were not reported. The patient's past medical history included palpitations, and concurrent conditions included allergies (sinus), and high blood pressure, and other pre-existing medical conditions included the patient had no known drug allergies.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805029, and batch number: 1805029 expiry: UNKNOWN) dose was not reported, administered on 09-MAR-2021 06:45 for prophylactic vaccination. No concomitant medications were reported. On MAR-2021, Laboratory data included: Body temperature (NR: not provided) 99.1 F. On 09-MAR-2021, the subject experienced palpitations. On 09-MAR-2021, the subject experienced headache. On 09-MAR-2021, the subject experienced fever. Laboratory data included: Body temperature (NR: not provided) 100.3 F. Treatment medications (dates unspecified) included: paracetamol. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from palpitations on 10-MAR-2021, was recovering from fever, and had not recovered from headache. This report was non-serious.; Sender's Comments: MAC- MAC not required per standard procedure as the case assessed as non-serious.
On 10/17/22, patient states she developed flu-like symptoms such as fever and bodyaches. The following day on 10/18/22, patient states flu-like symptoms resolved but she developed tingling in both hands and feet. She also developed a large erythematous patch over the injection site.
Patient received vaccination (FLUVIRIN from Novartis) on 11/5 9:15AM after 10 min he walked to his car with his son but blacked out and fainted. He states that he drove himself to hospital across the st. and was hospitalized 2 days. Pt would not provide details of treatment but stated that he received "blood thinner".
Floaters in my eyes.  Flashes of light in the corners of my eyes. Seeing shadows in my peripheral vision.
22 year old male patient stood after vaccination, walked a short distance towards recovery area, and fell face forward to the ground, hitting his face on the floor.   Provider turned patient to a supine position and noted eyes wide open, upper extremities stiffened, and unresponsive to verbal questions.  Napkin saturated with alcohol solution held under patient's nares.  Shortly thereafter, approximately 15 seconds after falling, patient began verbal communication.   Patient was initially A&Ox1; remembered his name but could not remember the date, his location, the event, or getting the vaccine.  Members of the team arrived to assist. EMS team arrived and continued assessment.
Pt started with redness, at injection site and temp. By the 19th patient was having trouble breathing and swallowing and was taken by ambulance to the ER.
This writer received a report form the nurse who administered the vaccine. She stated she administered the vaccine in the patient's abdomen (right quadrant). She indicated that the patient insisted that it be administered in his abdomen verses one of the correct intramuscular routes.  This patient did ano experience any adverse reaction from vaccine receivership.
Information has been received from a nurse practitioner concerning a "31 year old" female who on 14-DEC-2009 was vaccinated with a first dose of PNEUMOVAX 23 (therapy route and lot # not provided). On 18-JAN-2011 the patient received a second 0.5 ml dose of PNEUMOVAX 23 (therapy route not provided, lot # 665401/1320Y, expired date unspecified). On 18-JAN-2011 the patient experienced "tightness in the chest that radiated down through the arm of the injection site of PNEUMOVAX vaccine". Patient also experienced constant neck and back pain and woke up choking. Patient did not inform the office she had been vaccinated with PNEUMOVAX 23 on 14-DEC-2009 until after receiving the product again on 18-JAN-2011. The office asked if she had received it before administrating the product and the patient said she had not. Then after receiving the injection and experiencing symptoms she reported having the shot before. Treatment given for this adverse event included 600 mg MOTRIN. "Tightness in the chest that radiated down through the arm of the injection site", constant neck and back pain and woke up choking were considered to be immediately life-threatening, disabling and overdose. At the time of reporting, the patient is recovering. A lot check has been initiated. This is one of several reports received from the same source. Additional information has been requested.
PT EXPERIENCED DIFFICULTY BREATHING, CHEST PAIN, COUGH, SCRATCHY THROAT AND HIVES WITHIN 45 MINUTES OF RECEIVING VACCINE. HE ADMINISTERED HIS OWN EPI PEN AND MOM DROVE HIM TO ED. AFTER 4 HOURS OF OBSERVATION IN ED PT WAS DISCHARGED HOME.
Sick; coughing up yellow balls of mucus; bad cough; Lousy; Vaccination adverse reaction; Fatigued; Sweats; Fever; This case was initially received via an unknown source (no reference has been entered for a health authority or license partner) on 22-Mar-2021. The most recent information was received on 09-May-2021 and was forwarded to Moderna on 09-May-2021.    This spontaneous case was reported by a patient and describes the occurrence of VACCINATION COMPLICATION (Vaccination adverse reaction), HYPERHIDROSIS (Sweats), ILLNESS (Sick), INCREASED VISCOSITY OF UPPER RESPIRATORY SECRETION (coughing up yellow balls of mucus) and COUGH (bad cough) in a 73-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 09-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Mar-2021, the patient experienced HYPERHIDROSIS (Sweats) and PYREXIA (Fever). On an unknown date, the patient experienced VACCINATION COMPLICATION (Vaccination adverse reaction), ILLNESS (Sick), INCREASED VISCOSITY OF UPPER RESPIRATORY SECRETION (coughing up yellow balls of mucus), COUGH (bad cough), MALAISE (Lousy) and FATIGUE (Fatigued). At the time of the report, VACCINATION COMPLICATION (Vaccination adverse reaction), HYPERHIDROSIS (Sweats), ILLNESS (Sick), INCREASED VISCOSITY OF UPPER RESPIRATORY SECRETION (coughing up yellow balls of mucus), COUGH (bad cough), MALAISE (Lousy) and PYREXIA (Fever) outcome was unknown and FATIGUE (Fatigued) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 22-Mar-2021, SARS-CoV-2 test: negative (Negative) negative.         No concomitant medication was reported . No treatment medication was reported .   Most recent FOLLOW-UP information incorporated above includes: On 09-May-2021: Follow up received included dose number lab data e,vent outcome as recovered for fatigue and events such as cough and coughing up yellow balls of mucous
2 inch x 3 inch red indurated area back of right arm.  Warm & tender.  Treatment ice, Benadryl 25 mg orally at bedtime, Benadryl gel topically during school.
Fever, (101.5) headache, chills, large warm rash on left arm. Joint pain.
shingles on torso, under the right breast and on the thighs / lack of drug effect; arm soreness; This case was reported by a consumer via call center representative and described the occurrence of shingles in a 54-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included ramsay-hunt syndrome.   On 26th September 2019, the patient received the 1st dose of Shingrix (intramuscular). On 27th September 2019, 1 days after receiving Shingrix, the patient experienced shingles and pain in arm. The patient was treated with acyclovir. On an unknown date, the outcome of the shingles and pain in arm were unknown.   It was unknown if the reporter considered the shingles and pain in arm to be related to Shingrix.  Additional case details were reported as follows: The patient received vaccine in right arm. The next day, after vaccination the patient's arm was sore.  The patient also reported shingles that developed on her torso, under the right breast and on the thighs.  The patient was seen by her physician for the diagnosis and was prescribed acyclovir. The reporter consented to follow up.
In March 2021 a sinus infection started that did not respond to two rounds of antibiotics. Major sinus headache/pain that still persists after sinus surgery in February 2023 to dilate and extract fungus in sinus cavity at facility. Two bouts of Shingles, one in March 2021, another in June 2022. never had before. Insomnia started with head pain accompanied by nervous system  shaking, depression, anxiety, brain fog, exhaustion,  and heart palpitations.  Digestive issues of  constipation alternating with loose bowels and rashes. All this has slightly improved over the years but is still effecting my quality of life greatly.
Upon checking out patient began to feel lightheaded. Dr. looked pale and he sat down on the waiting bench. Pharmacist went out to check on him and patient lost consciousness (about 5 seconds) called 911. Patient regained consciousness and was alert when the EMT arrived. Patient was awake and responsive, patient waited 20 minutes and left on his own.
Chills body aches day of first shot and following day. Second shot felt like I had a fever but it only raised to 99. Fatigue and headache  and had a cold  august 17 2021 had what was possibly considered  TIA/Strokes  admitted in the hospital a few times during the week.
The 2nd dose of the Pfizer COVID-19 vaccine was given 13 days after the 1st dose - 1st dose given 9/7/21 & 2nd dose given 9/20/21.
severe itching; Hives; This spontaneous case was reported by an other health care professional and describes the occurrence of PRURITUS (severe itching) and URTICARIA (Hives) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032L20A, 004M20A and 022C21A) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Nov-2021, the patient experienced PRURITUS (severe itching) and URTICARIA (Hives). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Adverse event, at an unspecified dose and frequency and PREDNISONE for Adverse event, at an unspecified dose and frequency. On 05-Jan-2022, URTICARIA (Hives) had resolved. At the time of the report, PRURITUS (severe itching) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information was provided. The patient received the Moderna vaccine on 26-Nov-2021 (dose no. of vaccine not reported). The patient experienced adverse events from the steroids and stopped it's therapy. The patient took prednisone and Benadryl for about 12 days.
severe headaches; muscle spasms mainly in her legs; this second one has knocked her on her butt; could hardly keep her eyes open, she laid couch and fell sound asleep/ if she sits down she will fall asleep; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 68 year-old female patient received bnt162b2 (BNT162B2) (Lot number: EL9267, Expiration Date: 31May2021) as dose 2, single for covid-19 immunisation. Relevant medical history included: "suspected COVID-19", start date: Jan2020 (unspecified if ongoing), notes: doctor said they had a virus of some sort but they did not know what it was. There were no concomitant medications. Vaccination history included: Bnt162b2 (dose 1, single, Lot number: EL9267), for COVID-19 immunisation, reaction(s): "severe headaches", "muscle spasms mainly in her legs", "if she sits down she will fall asleep". The following information was reported: SOMNOLENCE (non-serious) with onset 22Feb2021, outcome "unknown", described as "could hardly keep her eyes open, she laid couch and fell sound asleep/ if she sits down she will fall asleep"; HEADACHE (non-serious), outcome "not recovered", described as "severe headaches"; MUSCLE SPASMS (non-serious), outcome "not recovered", described as "muscle spasms mainly in her legs"; FATIGUE (non-serious), outcome "unknown", described as "this second one has knocked her on her butt".  No follow-up attempts are needed. No further information is expected.
after receiving vaccine pt states that her arm had gotten swollen. she also had pain and had experienced limited range of motion. pt contacted her dr who advised her to use a warm compress. as of 1/17/21 pt states that her arm is getting better. the swelling has diminished as of a couple weeks ago & she is starting to regain use/motion of her left arm.
Sores produced al! over her body after receiving the injection; The reaction was accompanied by itching; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP and Other HCP). The reporter is the patient. Other Case identifier(s): 2020SA044245.  A 78 year-old female patient (not pregnant) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: SKIN LESION (non-serious), outcome "unknown", described as "Sores produced al! over her body after receiving the injection"; PRURITUS (non-serious), outcome "unknown", described as "The reaction was accompanied by itching".   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
This case was reported by a nurse practitioner and described the occurrence of transverse myelitis in a 49 year old female patient who received hepatitis B vaccine recombinant. On unspecified dates in 2003, the patient received the first two doses of Engerix B (lot ENG5384A2). On an unspecified date in January 2004, the patient received the third dose of Engerix-B (lot ENG5384A2). On an unspecified date in 2004, a hepatitis B surface antibody titer revealed that the patient was a non-responder. Subsequently, the patient received the fourth dose of Engerix-B on an unspecified date in March 2004 (lot number not provided). On an unspecified date in April 2004, the patient received the fifth dose of Engerix-B in the deltoid (lot ENG5514A2). Approximately three months after the fifth administration of Engerix-B, on an unspecified date in July 2004, after returning from a trip, the patient experienced transverse myelitis, right foot drop and right leg weakness. The patient was seen at a physician's office. MRI, performed on an unspecified date in July 2004, revealed a broad disk protrusion on the right side of L5 and S1. The events were ongoing at the time of initial reporting. The nurse practitioner considered the events to be unrelated to vaccination with Engerix B. Comment: Transverse myelitis and intervertebral disc protrusion were assessed as medically serious (OMIC).
This spontaneous report as received from a health professional refers to a 4 year old patient. On 07-MAY-2014 the patient was vaccinated with (Oka/Merck) VARIVAX lot # J012377, expiration date 03-OCT-2015, dose and route not reported and MMR II (lot # J003785, expiration date 28-MAR-2015, dose and route not reported) which were stored improperly. There was no adverse effect reported. This is one of several reports received from the same source. Additional information is not expected.
No addittional adverse effects reported; MMR II that underwent temperature excursions was administered; This spontaneous report was received from an unspecified reporter and refers to a patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported.  On 16-NOV-2021, the patient was vaccinated with an improperly stored dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) subcutaneous injection (lot #T033814, expiration date: 05-OCT-2022), administered for prophylaxis (strength, dose and route of administration were not provided), which had temperature excursions between 8.5C and 12.4C for time frames between 9 minutes and 53 minutes. The vaccine did not have previous temperature excursions and no additional adverse events were reported.  This is one of several cases from the same reporter.; Sender's Comments:  US-009507513-2112USA006870: US-009507513-2112USA007442: US-009507513-2112USA007425: US-009507513-2112USA007426: US-009507513-2112USA007427: US-009507513-2112USA007428: US-009507513-2112USA007429: US-009507513-2112USA007430: US-009507513-2112USA007431: US-009507513-2112USA007432: US-009507513-2112USA007433: US-009507513-2112USA007434: US-009507513-2112USA007435: US-009507513-2112USA007436: US-009507513-2112USA007437: US-009507513-2112USA007438: US-009507513-2112USA007439: US-009507513-2112USA007440: US-009507513-2112USA007441: US-009507513-2112USA007444: US-009507513-2112USA007445: US-009507513-2112USA007446: US-009507513-2112USA007447: